Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5539472 | 0.85 | CA12 (0.44) | LMNAGAATSPOCA12CA2 | |
| SCHEMBL5545985 | 0.78 | SRD5A1 (0.36) | CA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5539662 | 0.78 | GABRA1 (0.38) | CA2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5534507 | 0.77 | HCAR1 (0.34) | LMNAGAATSPOCA12CA2 | |
| SCHEMBL5544804 | 0.77 | PDE4A (0.37) | PDE4DGRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5538711 | 0.77 | HTR1A (0.33) | LMNAGAATSPOCA12CA2 | |
| SCHEMBL5546306 | 0.74 | TSHR (0.38) | CA12CA9KCNH2AADAT | |
| SCHEMBL21753084 | 0.73 | CASP1 (0.49) | LMNAGAAGABRA1GABRG2GABRB3 | |
| SCHEMBL10999775 | 0.73 | OPRK1 (0.47) | LMNAGAAOPRK1PDE4DMAT2A | |
| SCHEMBL2354261 | 0.72 | TTR (0.41) | LMNACA12CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-4530843-A | Containing a heterocyclic ring | SYNTHELABO (FR) | 1985-07-23 | — | — | US | disclosed |
| US-4530843-A | Containing a heterocyclic ring | SYNTHELABO (FR) | 1985-07-23 | — | — | US | disclosed |
| US-4438121-A | CENTRAL NERVOUS SYSTEM DISORDER TREATMENT, ANTIDEPRESSANTS | SYNTHELABO (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4438121-A | CENTRAL NERVOUS SYSTEM DISORDER TREATMENT, ANTIDEPRESSANTS | SYNTHELABO (FR) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | LMNA 4152/4885GAA 4165/4885TSPO 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.